Baylor College of Medicine 3rd Annual Opioid Use Disorder Conference 2025

Course opens: Friday, April 11, 2025 

The opioid use epidemic has been at the forefront of societal concerns in the United States. The DEA-MATE act requires all providers to adeptly prescribe and manage Opioid Use Disorder (OUD) and related issues. Treating teams face multiple challenges, including treating chronic pain, preventing over-prescription of opioids, and addressing illicit use. This conference will provide education on evidence-based treatment techniques, including pharmacologic and psychotherapeutic approaches, to manage OUD. Attendees will learn to recognize barriers to accessing medication, apply person-first language, and identify signs and symptoms of opioid use disorder and withdrawal. Additionally, attendees will gain knowledge on how to refer patients to appropriate resources for outpatient care, ultimately empowering them to initiate and/or maintain effective treatments for OUD with confidence.

TARGET AUDIENCE

This activity is for physicians and advanced-practice providers in psychiatry, emergency medicine, family medicine, internal medicine, and obstetrics and gynecology and the community.

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, the participants should be able to:

Apply treatment techniques, including pharmacologic and psychotherapeutic approaches, in managing Opioid Use Disorder.
Recognize barriers to accessing medication in treatment of Opioid Use Disorder treatment.
Recall and apply person first language, emphasizing the individual rather than the diagnosis, when interacting with patients diagnosed with Opioid Use Disorder.
Identify and appropriately respond to signs and symptoms of opioid use disorder and opioid withdrawal.

+ Topics:

01 A System Lens on Treating Patients with Substance Use Disorders

02 To Eliminate Hepatitis C, Treat Those Who Inject Drugs

03 Center for Behavioral Emergency and Addiction Research (CBEAR)

04 Managing Opioid Withdrawal in the Emergency Department – ED-Initiated Buprenorphine

05 What do Buprenorphine Levels Really Tell Us Quantitative Analyses in Relation to Clinical Response

06 Co-Occurring Stimulant and Opioid Use Disorders, A Clinical Challenge

07 Technology Advances in Substance Use Treatment

08 Expansion of Medications for Opioid Use Disorder in Correctional Facilities

09 Community-Based, Specialized SUD Treatment for Women and Families

10 ADHD, Opioids, and the Family – Protecting Vulnerable Youth

11 Implementation of a Tobacco-Free Workplace Program in Opioid Treatment Centers in Texas – Findings and Future Directions

12 The Pharmacology of CNS Depressant Polypharmacy That is Bringing Us Down